title: Neurofibromatosis type 2 tumor suppressor protein, NF2, induces proteasome-mediated degradation of JC virus T-antigen in human glioblastoma.
abstract: Neurofibromatosis type 2 protein (NF2) has been shown to act as tumor suppressor primarily through its functions as a cytoskeletal scaffold. However, NF2 can also be found in the nucleus, where its role is less clear. Previously, our group has identified JC virus (JCV) tumor antigen (T-antigen) as a nuclear binding partner for NF2 in tumors derived from JCV T-antigen transgenic mice. The association of NF2 with T-antigen in neuronal origin tumors suggests a potential role for NF2 in regulating the expression of the JCV T-antigen. Here, we report that NF2 suppresses T-antigen protein expression in U-87 MG human glioblastoma cells, which subsequently reduces T-antigen-mediated regulation of the JCV promoter. When T-antigen mRNA was quantified, it was determined that increasing expression of NF2 correlated with an accumulation of T-antigen mRNA; however, a decrease in T-antigen at the protein level was observed. NF2 was found to promote degradation of ubiquitin bound T-antigen protein via a proteasome dependent pathway concomitant with the accumulation of the JCV early mRNA encoding T-antigen. The interaction between T-antigen and NF2 maps to the FERM domain of NF2, which has been shown previously to be responsible for its tumor suppressor activity. Co-immunoprecipitation assays revealed a ternary complex among NF2, T-antigen, and the tumor suppressor protein, p53 within a glioblastoma cell line. Further, these proteins were detected in various degrees in patient tumor tissue, suggesting that these associations may occur in vivo. Collectively, these results demonstrate that NF2 negatively regulates JCV T-antigen expression by proteasome-mediated degradation, and suggest a novel role for NF2 as a suppressor of JCV T-antigen-induced cell cycle regulation.
authors: Department of Neuroscience and Center for Neurovirology, Temple University School of Medicine, Philadelphia, Pennsylvania, United States of America.
authors: Sarah
authors: S
authors: Beltrami
authors: Emanuela
authors: E
authors: Branchetti
authors: Ilker K
authors: IK
authors: Sariyer
authors: Jessica
authors: J
authors: Otte
authors: Michael
authors: M
authors: Weaver
authors: Jennifer
authors: J
authors: Gordon
mesh_terms: D000957:Antigens, Viral, Tumor / Q000235:genetics* / Q000378:metabolism; D001665:Binding Sites; D001706:Biopsy; D001932:Brain Neoplasms / Q000235:genetics* / Q000473:pathology / Q000821:virology; D002453:Cell Cycle / Q000235:genetics; D045744:Cell Line, Tumor; D015870:Gene Expression; D005909:Glioblastoma / Q000235:genetics* / Q000473:pathology / Q000821:virology; D006801:Humans; D007577:JC Virus / Q000502:physiology; D016518:Neurofibromatosis 2 / Q000235:genetics* / Q000378:metabolism; D027601:Polyomavirus Infections / Q000235:genetics* / Q000473:pathology / Q000821:virology; D011401:Promoter Regions, Genetic; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D059748:Proteolysis; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism; D014412:Tumor Virus Infections / Q000235:genetics* / Q000473:pathology / Q000821:virology; D025801:Ubiquitin / Q000235:genetics / Q000378:metabolism
chemical_list: D000957:Antigens, Viral, Tumor; D016159:Tumor Suppressor Protein p53; D025801:Ubiquitin; D046988:Proteasome Endopeptidase Complex